On October 22, 2026, TFP Fertility Group, a fertility provider with clinics in the UK and Poland backed by US private-equity firm Amulet Capital Partners, announced it had acquired Manchester Fertility Group. Financial terms were not disclosed. Manchester Fertility has been operating since 1986 and runs a purpose-built clinic and laboratory in Cheadle, Greater Manchester. The deal gives TFP its first major base in northwest England.

Why It Matters

Fertility care is consolidating on both sides of the Atlantic, as private-equity-backed groups buy up independent clinics. Last week we covered [IVI RMA buying Canada's Illume](/stories/ivirma-illume-fertility-acquisition). The UK version has a twist: donor-sperm and donor-egg supply is limited, regulated by the HFEA, and increasingly sold direct to consumers through brands like BuySperm. Combining donor banks with clinic networks gives the buyer pricing power over a scarce input that competing clinics need. For femtech and fertility-tech investors, this shows where value is gathering: physical lab capacity and donor inventory, not apps. Watch for HFEA scrutiny of donor-service pricing and for further roll-ups in the UK's fragmented independent sector.

The asset list is the interesting part. Manchester Fertility is made up of five brands: Manchester Fertility, Essential Fertility, Semovo, Egg Donors UK and BuySperm. Between them they offer treatment, fertility preservation and donor services to patients and to partner clinics across the UK. So TFP is buying a donor-gamete supply operation that other clinics rely on, not just another IVF clinic. "We see a natural fit between our businesses," said TFP group CEO Jude Fleming. Selling shareholders Debbie Falconer and Jonathan Koslover said they had found "an excellent long-term home for the business."

Sources

Update — 2026-10-27

Initial entry — story first created.